Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Inventiva S.A. Sponsored ADR has garnered a consensus recommendation of "Moderate Buy" from eight brokerages, with one sell, one hold, and six buy ratings issued.
• The average 12-month price target for the stock among analysts is $16.14, reflecting a notable range of price objectives from $9 to $26 among various analysts.
• Inventiva's stock recently experienced a 10.3% increase, opening at $5.47 and having a 52-week price range between $2.11 and $6.55.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.1429.

Several analysts have commented on IVA shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research note on Wednesday, October 8th. Guggenheim upped their price objective on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Piper Sandler initiated coverage on Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Finally, HC Wainwright boosted their target price on Inventiva from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, October 9th.

Inventiva Stock Up 10.3%

IVA opened at $5.47 on Thursday. The business has a 50 day moving average price of $5.23 and a two-hundred day moving average price of $3.98. Inventiva has a 52 week low of $2.11 and a 52 week high of $6.55.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,715 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.